A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation
Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8+ cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antig...
Gardado en:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
KeAi Communications Co., Ltd.
2024-07-01
|
| Series: | Bioactive Materials |
| Assuntos: | |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S2452199X24001269 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|